220 related articles for article (PubMed ID: 19475687)
1. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
Halilbasic E; Fiorotto R; Fickert P; Marschall HU; Moustafa T; Spirli C; Fuchsbichler A; Gumhold J; Silbert D; Zatloukal K; Langner C; Maitra U; Denk H; Hofmann AF; Strazzabosco M; Trauner M
Hepatology; 2009 Jun; 49(6):1972-81. PubMed ID: 19475687
[TBL] [Abstract][Full Text] [Related]
2. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
3. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
4. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
5. 24-Norursodeoxycholic acid reshapes immunometabolism in CD8
Zhu C; Boucheron N; Müller AC; Májek P; Claudel T; Halilbasic E; Baazim H; Lercher A; Viczenczova C; Hainberger D; Preglej T; Sandner L; Alteneder M; Gülich AF; Khan M; Hamminger P; Remetic J; Ohradanova-Repic A; Schatzlmaier P; Donner C; Fuchs CD; Stojakovic T; Scharnagl H; Sakaguchi S; Weichhart T; Bergthaler A; Stockinger H; Ellmeier W; Trauner M
J Hepatol; 2021 Nov; 75(5):1164-1176. PubMed ID: 34242699
[TBL] [Abstract][Full Text] [Related]
6. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
7. Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
Halilbasic E; Steinacher D; Trauner M
Dig Dis; 2017; 35(3):288-292. PubMed ID: 28249255
[TBL] [Abstract][Full Text] [Related]
8. Active enterohepatic cycling is not required for the choleretic actions of 24-norUrsodeoxycholic acid in mice.
Truong JK; Li J; Li Q; Pachura K; Rao A; Gumber S; Fuchs CD; Feranchak AP; Karpen SJ; Trauner M; Dawson PA
JCI Insight; 2023 Mar; 8(6):. PubMed ID: 36787187
[TBL] [Abstract][Full Text] [Related]
9. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice.
Krones E; Eller K; Pollheimer MJ; Racedo S; Kirsch AH; Frauscher B; Wahlström A; Ståhlman M; Trauner M; Grahammer F; Huber TB; Wagner K; Rosenkranz AR; Marschall HU; Fickert P
J Hepatol; 2017 Jul; 67(1):110-119. PubMed ID: 28242240
[TBL] [Abstract][Full Text] [Related]
10. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.
Sombetzki M; Fuchs CD; Fickert P; Österreicher CH; Mueller M; Claudel T; Loebermann M; Engelmann R; Langner C; Sahin E; Schwinge D; Guenther ND; Schramm C; Mueller-Hilke B; Reisinger EC; Trauner M
J Hepatol; 2015 Apr; 62(4):871-8. PubMed ID: 25463533
[TBL] [Abstract][Full Text] [Related]
11. Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice.
Wanek T; Halilbasic E; Visentin M; Mairinger S; Römermann K; Stieger B; Kuntner C; Müller M; Langer O; Trauner M
J Pharm Sci; 2016 Jan; 105(1):106-12. PubMed ID: 26852845
[TBL] [Abstract][Full Text] [Related]
12. Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
Trauner M; Halilbasic E; Claudel T; Steinacher D; Fuchs C; Moustafa T; Pollheimer M; Krones E; Kienbacher C; Traussnigg S; Kazemi-Shirazi L; Munda P; Hofer H; Fickert P; Paumgartner G
Dig Dis; 2015; 33(3):433-9. PubMed ID: 26045280
[TBL] [Abstract][Full Text] [Related]
13. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans.
Hofmann AF; Zakko SF; Lira M; Clerici C; Hagey LR; Lambert KK; Steinbach JH; Schteingart CD; Olinga P; Groothuis GM
Hepatology; 2005 Dec; 42(6):1391-8. PubMed ID: 16317695
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
Fickert P; Pollheimer MJ; Silbert D; Moustafa T; Halilbasic E; Krones E; Durchschein F; Thüringer A; Zollner G; Denk H; Trauner M
J Hepatol; 2013 Jun; 58(6):1201-8. PubMed ID: 23369794
[TBL] [Abstract][Full Text] [Related]
15. Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1 and NTCP.
König J; Klatt S; Dilger K; Fromm MF
Basic Clin Pharmacol Toxicol; 2012 Aug; 111(2):81-6. PubMed ID: 22333292
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
Steinacher D; Claudel T; Trauner M
Dig Dis; 2017; 35(3):282-287. PubMed ID: 28249257
[TBL] [Abstract][Full Text] [Related]
17. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.
Moustafa T; Fickert P; Magnes C; Guelly C; Thueringer A; Frank S; Kratky D; Sattler W; Reicher H; Sinner F; Gumhold J; Silbert D; Fauler G; Höfler G; Lass A; Zechner R; Trauner M
Gastroenterology; 2012 Jan; 142(1):140-151.e12. PubMed ID: 22001865
[TBL] [Abstract][Full Text] [Related]
18. 24-Norursodeoxycholic acid ameliorates experimental alcohol-related liver disease and activates hepatic PPARγ.
Grander C; Meyer M; Steinacher D; Claudel T; Hausmann B; Pjevac P; Grabherr F; Oberhuber G; Grander M; Brigo N; Jukic A; Schwärzler J; Weiss G; Adolph TE; Trauner M; Tilg H
JHEP Rep; 2023 Nov; 5(11):100872. PubMed ID: 37818230
[TBL] [Abstract][Full Text] [Related]
19. UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications.
Cabrera D; Arab JP; Arrese M
Handb Exp Pharmacol; 2019; 256():237-264. PubMed ID: 31236688
[TBL] [Abstract][Full Text] [Related]
20. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis.
Beraza N; Ofner-Ziegenfuss L; Ehedego H; Boekschoten M; Bischoff SC; Mueller M; Trauner M; Trautwein C
Gut; 2011 Mar; 60(3):387-96. PubMed ID: 21115542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
